Drug Approval | August 22, 2022
USFDA grants emergency use authorization for Novavax COVID-19 vaccine
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
The first wave of shipments includes several countries, such as Germany, France and Austria
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
It would be the first protein-based alternative available in Israel
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
Novavax' vaccine has received authorizations of the vaccine in over 170 countries
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)